Microfluidic chips with multiple arrays of microscopic posts coated with cancer-specific ABs (e.g., anti-EpCAM AB) increase the interactive surface between the putative CTCs in the bloodstream and the ABs, resulting in increased enrichment efficacy. The gene discussed is EPCAM; the disease is cancer.